ABOUT US

Bioprinting Laboratories Inc. has been exploiting “microarray three-dimensional (3D) bioprinting” technology and developing easy-to-use, disposable pillar/perfusion plates and bioprinted human mini-tissues derived from pluripotent stem cells (a.k.a., organoids). Our main products are injection-molded pillar/perfusion plates, designed for rapid and robust human organoid culture and analysis. These products can be used for 3D cell/tissue culture and predictive screening of compounds in the pharmaceutical, cosmetics, and chemical industries. Our mission is to enhance human safety and health by developing and providing pillar/perfusion plates, bioprinted human organoids on the pillar plates, and related toxicity/efficacy assessment services to serve global in vitro cell-based testing markets.

Image



     Problem & Opportunity


The demand for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips is immense. These alternatives are essential for improving the prediction of drug candidate toxicity and efficacy, thereby enhancing the success rate of screening new compounds during preclinical evaluations.


Due to the FDA Modernization Act 2.0, passed in December 2022, there is an enormous need for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips to better predict the toxicity and efficacy of new drug candidates and increase the success rate of compound screening in preclinical evaluations. BPL addresses critical customer needs in this market by combining the three alternative models into one pillar/perfusion plate platform. Recently, great advances have been made in organotypic 3D cell/tissue models, such as human organoids, for disease modeling. However, human organoid cultures have been performed on low-throughput platforms such as 6/24-well plates, petri dishes, and spinner flasks, which significantly limit their use in preclinical evaluations. BPL has targeted this bottleneck by developing innovative, microarray 3D bioprinting of human organoids in the pillar/perfusion plate and facilitating robust organoid culture and imaging in situ for predictive compound screening.




     Product & Solution


Our products are injection-molded pillar/perfusion plates (e.g., 36PillarPlate, 36PerfusionPlate, 144PillarPlate, 144PerfusionPlate, 384PillarPlate, and 384DeepWellPlate) and their accessories (36PetriLid, 144PetriLid, and LoadingPlate) for 3D cell and organoid cultures, as well as bioprinted human organoids on the pillar plates. Bioprinted human organoids can recapitulate physiologically relevant characteristics of tissues in vivo, thus providing more predictive insight into potential organ-specific toxicity of compounds. This system is cost-effective, high-throughput, and highly reproducible for various cell-based assays, with the capability of up- and down-regulation of specific disease genes in organoids using CRISPRai technology, which is essential for human disease modeling. Additionally, the pillar/perfusion plate system can simulate organ-organ interactions for accurate prediction of drug effects in humans.




     News



2025
Apr 1
Bioprinting Labs has been relocated to 4099 McEwen Road, Suite 450, Dallas, Texas 75244.




2024
Dec 17
Bioprinting Labs joined the 3Rs (Replacement, Reduction, and Refinement) Collaborative and became an official member of the MPS Tech Hub.


Jun 26
Dr. Lee has been selected as a finalist in the Business Plan Competition at the TERMIS World Congress 2024.


Jun 25
Bioprinting Laboratories Inc. attended the TERMIS World Congress 2024 and set up a booth to market pillar/perfusion plate products.


Jun 19
The first purchase order received from our customer for pillar/perfusion plate products.


Jun 10
Bioprinting Laboratories Inc. attended the MPS World Summit 2024 and set up a booth to market pillar/perfusion plate products.


Jun 5
Bioprinting Laboratories Inc. has officially launched pillar/perfusion plates and associated accessories for the static and dynamic culture of 3D cells and organoids in the market.


Mar 1
Bioprinting Laboratories Inc. established mass production protocols for pillar/perfusion plates and conducted beta tests with potential customers to ensure quality control.




Bioprinting Laboratories Inc.
4099 McEwen Road, Suite 450
Dallas, Texas  75244
Phone: (214) 730-0707
Email: [email protected]

Contact Us

Image